The frequency of TP53 and RB1 alterations in the SCLC cohort significantly exceeded that seen in our HGNECC cohort (15.5% and 8.2%, respectively), the HPV16/18 positive subset (11% and 4%, respectively), and the subset where HPV16/18 was not detected (43% and 36%, respectively; Table 2). This evidence concerns the gene RB1 and small cell lung carcinoma.